{"id":"minoxidil-5-topical-spray","safety":{"commonSideEffects":[{"rate":null,"effect":"Scalp irritation"},{"rate":null,"effect":"Dryness or flaking of scalp"},{"rate":null,"effect":"Itching"},{"rate":null,"effect":"Unwanted facial hair growth"},{"rate":null,"effect":"Contact dermatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Minoxidil acts as a vasodilator by opening ATP-sensitive potassium channels, which increases cutaneous blood flow to hair follicles and delivers more nutrients and oxygen to the dermal papilla. This stimulation extends the growth phase of hair and may increase hair follicle size, promoting hair regrowth in androgenetic alopecia. The exact mechanism in hair growth is not fully elucidated but involves improved follicle nutrition and potentially direct effects on follicle stem cells.","oneSentence":"Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:27.679Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Androgenetic alopecia (male and female pattern hair loss)"}]},"trialDetails":[{"nctId":"NCT07459933","phase":"PHASE4","title":"Topical Methotrexate vs Minoxidil for Localized Alopecia Areata","status":"NOT_YET_RECRUITING","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2026-03-15","conditions":"Alopecia Areata","enrollment":268},{"nctId":"NCT07273799","phase":"PHASE3","title":"Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Sheikh Zayed Federal Postgraduate Medical Institute","startDate":"2025-12-20","conditions":"Androgenic Alopecia","enrollment":200},{"nctId":"NCT06813963","phase":"PHASE4","title":"Minoxidil for Treating White Hair: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Southern Medical University, China","startDate":"2025-02-15","conditions":"Grey Hair","enrollment":100},{"nctId":"NCT06826001","phase":"PHASE2","title":"Various Procedural Treatment Options for Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Sheikh Zayed Medical College","startDate":"2025-02","conditions":"Androgenetic Alopecia","enrollment":190},{"nctId":"NCT06484881","phase":"PHASE3","title":"Clinical Study of Probiotic Treatment for Androgenetic Alopecia","status":"WITHDRAWN","sponsor":"Applied Biology, Inc.","startDate":"2024-09-15","conditions":"Androgenetic Alopecia, Female Pattern Baldness","enrollment":""},{"nctId":"NCT06333600","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Topical Vitamin D Analogue in Treatment of Female Pattern Hair Loss","status":"RECRUITING","sponsor":"Sohag University","startDate":"2023-05-20","conditions":"Dermatology, Female Pattern Baldness","enrollment":45},{"nctId":"NCT04481412","phase":"PHASE2, PHASE3","title":"Topical Cetirizine in Androgenetic Alopecia in Females","status":"COMPLETED","sponsor":"Cairo University","startDate":"2020-07-25","conditions":"Androgenetic Alopecia","enrollment":66},{"nctId":"NCT05587257","phase":"NA","title":"Role of Minoxidil in Alopecia Areata Transepidermal Drug Delivery of Minoxidil Via Either Fractional Carbon Dioxide Laser or Microneedling Versus Its Topical Nanoparticles Preparation for Treatment of Alopecia Areata","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-01-01","conditions":"Alopecia Areata","enrollment":60},{"nctId":"NCT05296863","phase":"PHASE3","title":"Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia","status":"COMPLETED","sponsor":"Dr. dr. Lili Legiawati, SpKK(K)","startDate":"2021-10-11","conditions":"Alopecia, Androgenetic, Hair Loss/Baldness","enrollment":37},{"nctId":"NCT03535233","phase":"PHASE4","title":"Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"Cairo University","startDate":"2016-03","conditions":"Alopecia Areata","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Minoxidil 5 % Topical Spray","genericName":"Minoxidil 5 % Topical Spray","companyName":"Sheikh Zayed Federal Postgraduate Medical Institute","companyId":"sheikh-zayed-federal-postgraduate-medical-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Minoxidil is a potassium channel opener that increases blood flow to hair follicles and prolongs the anagen (growth) phase of the hair cycle. Used for Androgenetic alopecia (male pattern baldness), Female pattern hair loss.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}